Hariharan D, Constantinides V A, Froeling F E M, Tekkis P P, Kocher H M
Queen Mary University of London, Institute of Cancer, Barts and the London School of Medicine and Dentistry, London, UK.
Eur J Surg Oncol. 2010 Oct;36(10):941-8. doi: 10.1016/j.ejso.2010.05.015. Epub 2010 Jun 12.
Staging laparoscopy (SL) may prevent non-therapeutic laparotomy in patients with otherwise resectable pancreatico-biliary cancers, but evidence is inconclusive. This meta-analysis aims to ascertain the true benefit of SL.
All studies undertaking SL as a diagnostic sieve were included and data homogenised. Standard meta-analytical tools with emphasis on sensitivity testing and meta-regression to detect the cause for heterogeneity between studies were used.
29 studies satisfied the criteria. 3305 patients underwent SL of which 12 were incomplete. Morbidity (n = 15) and mortality (n = 1) was low. True yield of SL for pancreatic/perpancreatic cancers (PPC) was 25% (95% CI 24-27) with a Diagnostic Odds Ratio (DOR) of 104 (95% CI 48-227). Resection rate improved from 61% to 80%. For proximal biliary cancers (PBC), SL increased the curative resection rate from 27% to 50%, with true yield of 47% (95% CI 42-52) and a DOR 61 (95% CI 19-189). Sub-group analysis for detection of liver and peritoneal lesions demonstrated a sensitivity of 88% (95% CI 83-92) and 92% (95% CI 84-96) for PPC; 83% (95% CI 69-92) and 93% (95% CI 81-99) for PBC, respectively. There was no between-study heterogeneity for peritoneal lesions. However for detection of local invasion, sensitivity was low: 58% (95% CI 51-65) for PPC and only 34% (95% CI 22-47) for PBC. Meta-regression did not reveal any cause for the observed heterogeneity between studies.
SL offers significant benefit to patients with resectable pancreatico-biliary cancers in avoiding non-therapeutic laparotomy and should be adopted in routine clinical practice in a judicious algorithm.
分期腹腔镜检查(SL)可能会避免对原本可切除的胰胆管癌患者进行非治疗性剖腹手术,但证据尚无定论。本荟萃分析旨在确定SL的真正益处。
纳入所有将SL作为诊断筛选手段的研究,并对数据进行同质化处理。使用了强调敏感性测试和元回归以检测研究间异质性原因的标准荟萃分析工具。
29项研究符合标准。3305例患者接受了SL,其中12例不完整。发病率(n = 15)和死亡率(n = 1)较低。SL对胰腺/胰腺周围癌(PPC)的实际检出率为25%(95%可信区间24 - 27),诊断比值比(DOR)为104(95%可信区间48 - 227)。切除率从61%提高到80%。对于近端胆管癌(PBC),SL将根治性切除率从27%提高到50%,实际检出率为47%(95%可信区间42 - 52),DOR为61(95%可信区间19 - 189)。检测肝脏和腹膜病变的亚组分析显示,PPC的敏感性为88%(95%可信区间83 - 92)和92%(95%可信区间84 - 96);PBC的敏感性分别为83%(95%可信区间69 - 92)和93%(95%可信区间81 - 99)。腹膜病变的研究间无异质性。然而,对于检测局部侵犯,敏感性较低:PPC为58%(95%可信区间51 - 65),PBC仅为34%(95%可信区间22 - 47)。元回归未揭示研究间观察到的异质性的任何原因。
SL对可切除的胰胆管癌患者避免非治疗性剖腹手术有显著益处,应在明智的算法中应用于常规临床实践。